Arcadia Biosciences earnings release, May 14, 2026

Arcadia Biosciences, Inc. (RKDA) · Form 8-K, Item 2.02 · Filed · SEC filing

Arcadia Biosciences (RKDA) Announces First Quarter 2026

Financial Results and Business Highlights

-- Zola® volumes increase 18% year-over-year --

-- SG&A at lowest level in Arcadia’s history --

DALLAS, Texas (May 14, 2026) – Arcadia Biosciences, Inc.®

(Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the first quarter of 2026.

“We are very pleased with our performance during the first quarter of 2026,” said T.J. Schaefer, CEO of Arcadia. “We were able to bring in gross proceeds of approximately $2.1 million from the exercise of previously outstanding preferred investment options, Zola® coconut water revenues and volumes increased at a double-digit rate compared to the same quarter last year, and our selling, general, and administrative expenses are at the lowest level in Arcadia’s history as a public company.

“Going forward, we continue to evaluate strategic alternatives but also remain focused on growing our Zola coconut water brand and are excited about the prospects of launching a new product that we expect to be on the shelves of many of our largest customers this fall,” Schaefer added.

Arcadia Biosciences, Inc.

Financial Snapshot

(Unaudited)

($ in thousands)¹

More detailed financial information is included in the company’s Report on Form 8-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), available in the Investors section of the company’s website under

SEC Filings.

Revenues

Sales of Zola coconut water unit volumes increased 18% and also benefitted from a price increase that went into effect at the beginning of the year. However, reported revenues decreased $100,000, or 8%, during the first quarter of 2026 compared to the same period in 2025, driven primarily by a revenue reserve release of approximately $193,000 in 2025.

Operating Expenses

Total operating expenses increased by $1.2 million during the first quarter of 2026 compared to the same period in 2025 due to the $750,000 gain on sale of the company’s reduced gluten and oxidative stability patent portfolios and $1.0 million gain related to the change in fair value of contingent consideration liability in the first quarter of 2025.

Cost of revenues increased $18,000, or 3%, during the first quarter of 2026 compared to the same period in 2025 driven primarily by the increase in Zola sales volume, which increased product costs and freight expenses.

Selling, general, and administrative expenses decreased by $559,000 during the first quarter of 2026 compared to the same period in 2025, driven primarily by the absence of M&A fees and lower employee costs in the first quarter of 2026.

Net Loss (Income) Attributable to Common Stockholders

Net loss attributable to common stockholders for the first quarter of 2026 was $4.4 million, or $2.11 per share, a $7.0 million decrease from the $2.6 million net income, or $1.90 per share, for the first quarter of 2025. The decrease was primarily driven by the loss relating to the company’s January 2026 warrant inducement offer transaction of $2.9 million and other loss of $1.5 million, in addition to the $750,000 gain on sale of the company’s reduced gluten and oxidative stability patent portfolios and $1.0 million gain related to the change in fair value of contingent consideration liability in the first quarter of 2025.

About Arcadia Biosciences, Inc.

Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.

Safe Harbor Statement

Financial statements

Income Statement

Three Months Ended March 31, — (In thousands, except share data and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenues:Product1,1001,200
Revenues:Total revenues1,1001,200
Operating expenses (income):Cost of revenues700682
Operating expenses (income):Gain on sale of intangible assets-750
Operating expenses (income):Change in fair value of contingent consideration-1,000
Operating expenses (income):Selling, general and administrative1,1791,738
Operating expenses (income):Total operating expenses1,879670
Operating expenses (income):(Loss) Income from continuing operations-779530
Operating expenses (income):Interest income5207
Operating expenses (income):Other loss, net-1,504
Operating expenses (income):Loss on January 2026 Inducement Offer-2,877
Operating expenses (income):Change in fair value of common stock warrant and option liabilities1,1911,862
Operating expenses (income):Issuance and offering costs-421
Operating expenses (income):Net income (loss) from continuing operations-4,3852,599
Operating expenses (income):Net (loss) income attributable to common stockholders-4,3852,599
Net (loss) income per share attributable to common stockholders:Basic-2.111.9
Net (loss) income per share attributable to common stockholders:Diluted-2.111.9
Weighted-average number of shares used in per share calculations:Basic2,082,8871,366,060
Weighted-average number of shares used in per share calculations:Diluted2,082,8871,366,203
Other comprehensive income (loss), net of taxUnrealized gains on available-for-sale securities$—$—
Other comprehensive income (loss), net of taxOther comprehensive income$—$—
Other comprehensive income (loss), net of taxComprehensive income (loss) attributable to common stockholders-4,3852,599

Income Statement

Three Months Ended March 31, — ($ in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025Three Months Ended March 31, – Favorable / (Unfavorable)Three Months Ended March 31, – Favorable / (Unfavorable) – $Three Months Ended March 31, – Favorable / (Unfavorable) – %
Total revenues1,1001,200-100-8.0%
Total operating expenses1,879670-1,209-180.0%
(Loss) income from continuing operations-779530-1,309-247.0%
Net (loss) income attributable to common stockholders-4,3852,599-6,984-269.0%

Balance Sheet

March 31, 2026 — (In thousands, except share data)

March 31, 2026December 31, 2025
Current assets:Cash and cash equivalents954259
Current assets:Short-term investments2,7664,304
Current assets:Accounts receivable and other receivables, net of allowance for credit loss of $559 as of March 31, 2026 and December 31, 2025425425
Current assets:Inventories8401,212
Current assets:Prepaid expenses and other current assets184156
Current assets:Total current assets5,1696,356
Current assets:Property and equipment, net8
Current assets:Intangible assets, net3939
Current assets:Other noncurrent assets115143
Current assets:Total assets5,3236,546
Current liabilities:Accounts payable and accrued expenses1,1021,789
Current liabilities:Other current liabilities263270
Current liabilities:Total current liabilities1,3652,059
Current liabilities:Common stock warrant and option liabilities1,073347
Current liabilities:Total liabilities2,4382,406
Stockholders’ equity:Common stock, $0.001 par value—150,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 2,056,884 and 1,373,120 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively6665
Stockholders’ equity:Additional paid-in capital288,421285,292
Stockholders’ equity:Accumulated deficit-285,602-281,217
Stockholders’ equity:Total stockholders' equity2,8854,140
Stockholders’ equity:Total liabilities and stockholders’ equity5,3236,546

Cash Flow

Three Months Ended March 31, — (In thousands) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)-4,3852,599
Adjustments to reconcile net income to cash used in operating activities:Change in fair value of common stock warrant and option liabilities-1,191-1,862
Adjustments to reconcile net income to cash used in operating activities:Change in fair value of contingent consideration-1,000
Adjustments to reconcile net income to cash used in operating activities:Issuance and offering costs421
Adjustments to reconcile net income to cash used in operating activities:Loss on January 2026 Inducement Offer2,877
Adjustments to reconcile net income to cash used in operating activities:Depreciation813
Adjustments to reconcile net income to cash used in operating activities:Lease amortization104
Adjustments to reconcile net income to cash used in operating activities:Amortization of note receivable-69
Adjustments to reconcile net income to cash used in operating activities:Gain on sale of intangible assets-750
Adjustments to reconcile net income to cash used in operating activities:Unrealized loss subsequent to receipt of Above Food Ingredients, Inc. common stock1,538
Adjustments to reconcile net income to cash used in operating activities:Stock-based compensation1578
Adjustments to reconcile net income to cash used in operating activities:Accounts receivable and other receivables-193
Adjustments to reconcile net income to cash used in operating activities:Inventories372-381
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations concerning the company and its products, including, but not limited to, statements relating to Zola products and sales, the company’s growth, cash position, operating costs, financial performance, evaluation of possible strategic alternatives and² transactions, and the impact on shareholder value. Undue reliance should not be placed on any forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from the results anticipated by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2025 (the 2025 Form 10-K), and other filings that the company makes with the SEC. Forward-looking statements concerning anticipated future activities also assume that the company has sufficient funding to continue its operations and planned activities, which may not be the case. As described in greater detail in the 2025 Form 10-K and in the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, the company will require additional funding in the near future to continue its operations and planned activities. There are no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms. The company may seek to raise additional funds through equity or debt financings, through transactions involving its other assets, or through other transactions. Any sale of additional equity securities could result in dilution to company stockholders. Reported results should not be considered as an indication of future performance. Forward-looking statements made in this press release speak only as of the date hereof, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements or to reflect events or circumstances arising after the date of this press release.

Arcadia Biosciences Contact:

T.J. Schaefer ir@arcadiabio.com

###³

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Arcadia Biosciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.